Clinical trials: 5-Fluorouracil
Colorectal Cancer, Neoadjuvant Chemotherapy
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
Colorectal cancer is the fourth most common cancer in China. Up to 30% of patients with colorectal cancer present with an emergency obstruction of the large bowel at the time of diagnosis, and 70% of all malignant obstruction…
- Conditions
- Colorectal Cancer, Neoadjuvant Chemotherapy, Stent, Obstruction
- Trial name
- NACSOC (NCT02972541)
- Testing
- Stenting with neoadjuvant chemotherapy, Stenting with immediate Surgery
- Where
- 32 sites in China
- Volunteers
- 248 people
- Sponsor
- Beijing Chao Yang Hospital
Unresectable/Metastatic Colorectal Cancer
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
FOLFOXIRI-based regimen is more used as a first-line therapeutic approach for patients diagnosed with unresectable or metastatic colorectal cancer for its superior efficacy.
- Trial name
- NCT06148402
- Testing
- Fruquintinib plus camrelizumab and capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Stomach Neoplasm, Gastrointestinal Neoplasms
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
Our main objective is to evaluate the effect of Ocoxin-Viusid on the quality of life of patients with advanced stomach cancer and esophagogastric junction.
- Conditions
- Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Esophageal Neoplasms
- Trial name
- NCT03549494
- Testing
- Ocoxin-Viusid®
- Where
- Cuba
- Volunteers
- 45 people
- Sponsor
- Catalysis SL
Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal…
- Trial name
- NCT07643623
- Testing
- tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab, Ipilimumab N01
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
Phase II - Treatment Regimen Exploration Stage: 1. Evaluate the safety and efficacy of the following three treatment regimens: Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart (Group A) Liposomal irinotecan + 5-FU/LV +…
- Conditions
- Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line
- Trial name
- NCT07585279
- Testing
- Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart, Irinotecan liposome + 5-FU/LV + Bevacizumab, Irinotecan + 5-FU/LV + Bevacizumab
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Hebei Medical University Fourth Hospital
Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy
Lidocaine for Oxaliplatin-induced Neuropathy
Oxaliplatin-induced neuropathy is a major dose-limiting side effect in patients with colorectal cancer treated with the FOLFOX chemotherapy regimen.
- Conditions
- Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer
- Trial name
- NCT03254394
- Testing
- Lidocaine Hydrochloride, FOLFOX regimen
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Gastrointestinal Cancer, Gastrointestinal Neoplasms
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms
- Trial name
- NCT03597581
- Testing
- ompenaclid, FOLFIRI, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 89 people
- Sponsor
- Inspirna, Inc.
Breast Cancer
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel followed by surgery in…
- Trial name
- NCT00003953
- Testing
- filgrastim, CMF regimen, docetaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Case Comprehensive Cancer Center
Advanced Pancreatic Carcinoma
A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer
A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy
- Trial name
- NCT05257122
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Esophageal Neoplasms
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as…
- Trial name
- NCT03189719
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 749 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cancer, Pancreatic Cancer
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
The purpose of this study is to evaluate the safety and impact on survival with treatment with 90-Y glass microspheres in conjunction with leucovorin, 5-fluorouracil (5-FU) and oxaliplatin (FOLFOX) as second-line treatment with…
- Trial name
- NCT01581307
- Testing
- FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin), TheraSpheres
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
The goal of this clinical trial is to test the safety of the trifluridine/tipiracil as replacement of fluoropyrimidines based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with…
- Conditions
- Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
- Trial name
- TRIFLUOX-DP (NCT06245356)
- Testing
- Lonsurf, Oxaliplatin, Panitumumab
- Where
- 21 sites in France
- Volunteers
- 73 people
- Sponsor
- UNICANCER
Loco-regional Esophageal Cancer
Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma
The purpose of this study is to determine whether bevacizumab can improve the outcome of treatment for patients with esophageal cancer whose disease is confined to the esophagus or the closely surrounding lymph nodes.
- Trial name
- NCT00570531
- Testing
- Bevacizumab, Paclitaxel, Cisplatin
- Volunteers
- 6 people
- Sponsor
- University of Michigan Rogel Cancer Center
Potentially Resection, Hepatocellular Carcinoma
TACE-HAIC vs. HAIC for Potentially Resectable HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- NCT03591705
- Testing
- TACE-HAIC, HAIC
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Sun Yat-sen University
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00003956
- Testing
- fluorouracil, leucovorin calcium, lonafarnib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Colorectal Cancer
Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer
The combination of oxaliplatin, 5-FU, leucovorin, and capecitabine is hypothesized to retain and potentially improve upon the activity of the FOLFOX regimens.
- Trial name
- NCT00205322
- Testing
- chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Wisconsin, Madison
Pancreatic Cancer
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
The purpose of this study is to treat participants with the combination of CPI-613 (the study drug) with FOLFIRINOX (the standard combination of drugs) to determine if it is safe and effective for participants with localized and…
- Trial name
- NCT03699319
- Testing
- CPI 613, Oxaliplatin, Irinotecan
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- David Bajor, MD
Colo-rectal Cancer
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
This is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and cetuximab + modified XELOX[mXELOX] (group B).
- Trial name
- NCT05074966
- Testing
- Experimental: mXELOX plus cetuximab, Active Comparator: FOLFOX plus cetuximab
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer
Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR
patients with metastatic colorectal cancer who were initially RAS wild and failed at least 2 lines of chemotherapy will be enrolled. Anti-EGFR must have been given in 1st line.
- Trial name
- REPAN (NCT03940131)
- Testing
- Panitumumab
- Where
- Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- King Abdullah Medical City
Pancreatic Neoplasms, Neoplasm Metastasis
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
The study explores the efficacy and safety of oxaliplatin combined with irinotecan liposome injection II via hepatic arterial infusion (HAIC) followed by sequential treatment with 5-FU/LV (HAIC) or oral administration of S-1 in…
- Conditions
- Pancreatic Neoplasms, Neoplasm Metastasis, Hepatic Metastasis of Pancreatic Cancer
- Trial name
- NCT06538623
- Testing
- Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin, Tegodor
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.